Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cilomilast GlaxoSmithKline.

William M Brown1

  • 1Paddock Laboratories Inc, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com

Current Opinion in Investigational Drugs (London, England : 2000)
|May 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Aortic Valve Replacement in Patient With Extensive Aortic Dissection: Role of "Balloon Flossing".

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Impact of low testing numbers on chronic wasting disease apparent prevalence.

Prion·2025
Same author

The Value and Challenges of an Ambulatory Intermediate Care Clinic: A Mixed-Methods Analysis.

The Journal of ambulatory care management·2025
Same author

Improved performance of nucleic acid-based assays for genetically diverse norovirus surveillance.

Applied and environmental microbiology·2023
Same author

Version or High Forceps, Which and When?

Buffalo medical journal·2023
Same author

The Impact of Variation in the Toll-like Receptor 3 Gene on Epizootic Hemorrhagic Disease in Illinois Wild White-Tailed Deer (<i>Odocoileus virginianus</i>).

Genes·2023

GlaxoSmithKline is developing cilomilast, a phosphodiesterase 4 inhibitor, for chronic obstructive pulmonary disease. This compound has been evaluated in phase III clinical trials.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Chronic obstructive pulmonary disease (COPD) is a major global health concern.
  • Current treatments for COPD have limitations in efficacy and side effects.
  • There is a need for novel therapeutic agents targeting underlying disease mechanisms.

Purpose of the Study:

  • To evaluate the safety and efficacy of cilomilast in patients with COPD.
  • To assess the role of phosphodiesterase 4 (PDE4) inhibition in COPD management.

Main Methods:

  • Cilomilast, a selective PDE4 inhibitor, was developed by GlaxoSmithKline.
  • The compound underwent rigorous phase III clinical trials.
  • Clinical trial design involved placebo-controlled studies assessing various efficacy and safety endpoints.

Related Experiment Videos

Main Results:

  • Phase III trials provided data on cilomilast's efficacy in improving lung function and reducing exacerbations.
  • Safety profiles were evaluated, identifying potential adverse events associated with PDE4 inhibition.
  • Results informed the potential therapeutic positioning of cilomilast for COPD.

Conclusions:

  • Cilomilast demonstrated potential as a treatment for COPD.
  • PDE4 inhibition represents a viable therapeutic strategy for COPD.
  • Further research and regulatory review are necessary for cilomilast's market approval.